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ABSTRACT
There has been a marked decline in the industrial research aimed at discovering novel antibacterial
agents, including new drugs that target resistant organisms. While this decline may reﬂect past cyclical
changes that often affect resource allocation at pharmaceutical companies, this decline is occurring at a
time of increasing levels of antibacterial drug resistance and meagre pipelines of new agents that are
active against them. There are multiple reasons for this decline, although few are unique to antibacterial
drug discovery research. These include: lack of industry productivity, increasing size of clinical trials,
increased generic competition and other pressures on drug pricing, a crowded and confused
marketplace and industry consolidation. And while many (if not most) large companies and biotechs
have exited the ﬁeld or severely curtailed their research, others have made it a point to continue their
efforts, citing both the unmet medical need and a large and apparently growing market. Despite the fact
that some companies have remained engaged, the view here is that the current level of industrial effort
is insufﬁcient to sustain a healthy ﬂow of new and better agents that are needed to counter the imminent
threat of bacterial drug resistance. Therefore, a clear and urgent need for ﬁnding ways to improve the
level and quality of industrial research in this area is apparent.
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RESISTANCE MATTERS
The increase in the levels of antibacterial drug
resistance in serious human pathogens has been
well documented and oft repeated to the point
of cliche´. Numerous studies [1–4] have shown
that the frequency of multidrug-resistant isolates
is increasing in US hospitals and throughout the
world. For severely ill, hospitalised patients,
therapeutic efﬁcacy is important to ultimate
morbidity and mortality, and therefore, to the
overall cost of care; however, there have been
very few studies concerning the actual costs of
antibacterial resistant infections. For many of
these pathogens, especially among the Gram-
negative bacteria, options for therapy are becom-
ing extremely limited and, while reports of
mortality to pan-resistant infections are mainly
anecdotal, it will not be long before they are
easily quantiﬁable, meaning that we are already
too late in the discovery and development of
novel antibiotics.
A BRIEF HISTORY OF
ANTIBACTERIAL DRUG DISCOVERY
The pharmaceutical industry owes much of its
early prosperity to the discovery of antibacterial
agents. The identiﬁcation of these virtually mira-
culous, life-saving drugs and the manufacture of
related analogues have obviously beneﬁtted to
society. Early antibacterial agents discovered were
the sulfonamides, penicillin and streptomycin,
and these were rapidly followed by tetracyclines,
isoniazid, macrolides, glycopeptides, cephalospo-
rins, nalidixic acid and other molecular classes
culminating in rifampicin which was marketed in
the late 1960s. It is worth noting that, despite its
discovery in 1928, it required a consortium of ﬁve
pharmaceutical companies (Abbott, Lederle,
Merck, Chas. Pﬁzer and ER Squibb & Sons) and
the US Department of Agriculture to develop and
produce penicillin in the 1940s, mainly as part of
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the war effort during the Second World War. The
cephalosporins became popular during the 1970s,
with several ‘second’ and ‘third’ generation prod-
ucts entering the marketplace by the mid-1980s.
Coincident with the growing market dominance
of the third generation cephalosporins was the
emergence of the pandemic of multiply resistant
Streptococcus aureus infections in US hospitals [5]
and Streptococcus pneumoniae in the community [6].
At that time, in the early 1980s, the pharmaceutical
industry began scaling back on their antibacterial
drug discovery efforts with approximately half of
large US and Japanese pharmaceutical companies
ending or curtailing their efforts [7,8]. Yet antibac-
terial drug discovery efforts did continue at many
major European and US pharmaceutical compan-
ies through the 1990s and these efforts led to
the introduction of quinupristin-dalfopristin
(Synercid) and linezolid (Zyvox), both target-
ing Gram-positive pathogens, to the marketplace
in 1999 and 2001. Linezolid is the ﬁrst of a new
class (oxazolidinones) of antibacterial agents to be
marketed since rifampicin. But since 1999 the
industry has once again pulled back from anti-
infective research in an even more concerted
manner, with 10 of the 15 largest companies
ending or curtailing their discovery efforts. While
this was occurring the industry has been experi-
encing a series of mega-mergers leading to large-
scale consolidation. Five modern pharmaceutical
companies (Pﬁzer, GlaxoSmithKline, Novartis,
Bristol-Myers Squibb and Aventis) actually are
comprised of 32 progenitor companies, all in
business as recently as 1980 (Fig. 1); many of
those 32 companies had their own antibacterial
groups, so consolidation alone has resulted in a
major decrease in the hunt for novel antibacterial
agents.
WHY STAY IN?
While many large companies have either dimin-
ished or eliminated their research efforts in anti-
bacterial drug discovery, some, including Johnson
& Johnson, Merck, Bayer and Pﬁzer (as well as a
few biotechnology companies) have elected to
remain in the ﬁeld. This persistence is basedmainly
on the existing, proﬁtable franchises these compa-
nies have in the antibacterial drug market, but also
upon the (accurate) view that resistant pathogens
will continue to emerge and disseminate. There-
fore, it is reasoned, there remains both an unmet
medical need and a commercial opportunity in the
future, although perhaps not to the same extent as
for some other therapeutic areas.
WHAT DOES IT TAKE TO DEVELOP A
NEW DRUG?
In determining research priorities pharmaceutical
companies consider the unmet medical need, and
the potential patient population that may be
treated by a new product, how that new product
would be differentiated from competition, the
price that a new product would fetch in different
markets (especially developed countries), the
investment that would be required to bring prod-
uct to market, and the costs to promote the new
drug. Because of increasing requirements by reg-
ulatory agencies in the areas of manufacturing,
safety and efﬁcacy for product development in
general, the pharmaceutical industry is bearing an
ever higher cost burden for each product brought
to market. To illustrate: the number of patients
enrolled in clinical trials for each new drug appli-
cation (NDA) in the 1981–84 period averaged 1321,
that number hadmore than tripled to 4237 by 1994–
95 [9], with the trend continuing ever upward
since. Combining this with postmarketing com-
mitments (i.e., additional, required clinical studies
even after a drug makes it to the market) and ever
more restrictive labelling (severely constraining
how a drug can be used or whether its expense can
be reimbursed),many (if notmost) approveddrugs
never recoup the investment required to bring
them to the market. The latest Tufts Center survey
indicates that these costs exceed US $800 m [10]
and may even be approaching $1 bn. Therefore,
pharmaceutical companies have been ever more
cognisant of the market potential for each new
medication and prioritise accordingly.
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Fig. 1. Contraction of the pharmaceutical industry with
time, indicated by the number of companies that now form
Pﬁzer, GlaxoSmithKline, Novartis, Bristol-Myers Squibb
and Aventis.
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CLINICAL TRIALS AND
TRIBULATIONS
Both the greatest unmet medical need and the
projected market growth are in the area of hospi-
tal-based infections and parenteral drugs. Clinical
trials for parenteral products, however, especially
those targeting speciﬁc resistant pathogens, are
quite expensive, with at least 600–1000 patients
per trial at costs of $5 000 or more per patient [11];
and multiple indications (and therefore multiple
trials) are required for market viability. The
International Committee on Harmonization
(ICH) has put forth proposed guidelines requiring
an increase in stringency for the active compara-
tor, noninferiority trials used for registration of
most antibacterial agents. The FDA then notiﬁed
some companies that the stringency of the trials
required for registration would be increased along
the lines suggested by the ICH, thus dramatically
increasing costs and time to market for antibacte-
rial drugs. Taken together with the challenges
discussed above this caused manywithin industry
to question the relative value of antibacterial drug
discovery. In consultation with the Pharmaceuti-
cal Manufacturer’s Association (PhRMA) and the
Infectious Diseases Society of America (IDSA),
the US FDA has somewhat revised its views on the
level of stringency for all possible applications of
antibiotics [11]. However, little has been actually
done to motivate companies to develop novel
agents that are active against resistant pathogens.
What is needed is for sponsors to have a clear
understanding in the review process of what an
acceptable drug proﬁle would be, in terms of both
safety and efﬁcacy, prior to the start of Phase III
pivotal studies. This would undoubtedly result in
more compounds being tested in proof of concept
studies (e.g., Phase II) but fewer, yet higher
quality, agents being tested in the large Phase III
studies. To date, the regulatory authorities have
not been able to formulate clear guidance on what
it would take to bring a novel antibacterial, with
activity towards resistant strains, to the market.
Indeed there has been much talk about the
regulatory review times as an important issue for
industry. Faster review times by regulatory
authorities are always well appreciated by the
industry but they are really not the issue. As
pointed out by the former Commissioner of the
FDA, Dr Mark McClellan, drugs spend only
approximately 10% of their time under regulatory
review in the period from discovery to marketing.
2 Instead, the real problem is the demand for more
and ‘higher quality’ data that require longer and
more expensive clinical testing, well before the
ﬁling of new drug applications, which results in
time lines that erode the patent life and commer-
cial viability of a new agent.
It has been suggested that while big pharmaceu-
tical companies will not ﬁnd and develop novel
antibacterial drugs, biotech companieswill pick up
the slack. Biotech companies, however, have to
date had a poor record in discovering novel
antibacterial agents and many of these companies
have simply ceased to exist. Some biotechs, like
Cubist, actually are developing drugs, like dapto-
mycin (which was discovered at Eli Lilly), origin-
ally found by large pharmaceutical companies. As
Cubist discovered, however, it is really just as
expensive to develop a narrow spectrum, niche
(and therefore less proﬁtable) antibiotic like dap-
tomycin as it is to develop a broad spectrum (and
probably more proﬁtable) antibiotic. In general,
biotechs rely on large companies to provide the
funding for the large Phase III pivotal clinical trial
studies. With fewer large companies in the ﬁeld,
and even fewer large companies to do business
withdue to consolidation, it is not clearwhether the
large industrial entitieswill be there topartner such
projects.
A tool commonly used in the prioritisation and
fallibility of market research is the Net Present
Value (NPV) calculation [12]. The NPV is a
determination of the value of a given project after
projecting expenses and revenues into the future
and discounting for the potential investment
value of the money that will be spent in executing
the project. NPV is usually ‘risk-adjusted’ (the
rNPV) with increased risk associated with pro-
jects at earlier stages; risks are different depend-
ing on factors such as the therapeutic target and
type of compound. Antibacterial agents that enter
development at all stages of development
through Phase III clinical trials have a relatively
low risk compared with projects in other thera-
peutic areas [13]. By way of example, a hypothet-
ical project entering clinical trials for a novel
antidepressant has been calculated at one com-
pany to have a rNPV of $720 m compared with
$100 m for a novel injectable antibacterial target-
ing susceptible and resistant Gram-positive bac-
teria. But if an increase in clinical trial size
or a post-marketing commitment is factored in,
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because of changes in the regulatory process, the
rNPV would drop relative to most other projects
(therefore the imposition of the ‘infamous’ 10 per
cent delta rule (see below), rather than the
previously deﬁned less stringent delta, would
result in an rNPV of $35 m, ranking the project
near the bottom of most companies’ projects).
However, NPVs are calculated according to the
rather inexact science of market research and they
often fail to take competitive drug discovery
programmes into consideration (rather, bench-
marking based on currently marketed products).
Given the fallibility of the assumptions used to
calculate NPVs, most companies also take other
factors into consideration, such as peak year sales
and compounded annual growth rates. Some
companies set a minimum peak sales ﬁgure
(e.g., $200 m or $500 m) and reject projects based
on projected peak sales less than that ﬁgure. In
terms of prioritisation of projects, a community-
based oral antibiotic would receive a more
favourable status than an injectable agent to treat
only vancomycin-resistant enterococci. Still both
of these would receive a lower priority than a
drug to treat depression. However, because sales
projections are made before hard clinical data are
available, the reality of how a drug is used once it
reaches the market often bears little resemblance
to the target product proﬁle; these disparities are
the rule more often than the exception.
UNIQUELY CHALLENGED
While antibacterial projects entering clinical
development have better rates of success than
those in other therapeutic areas [13,14], antibac-
terial drug discovery faces unique challenges.
First, the scientiﬁc challenge is a signiﬁcant one.
Although nearly 15 years after the emergence of
the ﬁeld of bacterial genomics, there are no
promising antibacterial agents in clinical devel-
opment or on the market derived via this tech-
nology. Perhaps it is unfair to expect that a decade
and a half of work in a novel technological area
would give rise to ﬁrst generation agents that are
superior to current agents that have been opti-
mised over the last 60 years. Indeed, target-based
drug discovery for novel antibacterials confronts
another unique problem: even a relatively nar-
row-spectrum agent would have to be active, not
against a single molecular target, but a family of
targets that are similar but far from identical.
Recent publications, however, suggest that target-
based drug discovery is starting to pay off.
Inhibitors of peptide deformylase [15] are enter-
ing clinical development and novel inhibitors of
fatty acid biosynthesis have been described [16].
Perhaps even more vexing is the ‘antibiotic
paradox’. As we have seen, the rise of multiply-
resistant S. aureus infections led to increased
usage of vancomycin, but after a period of heavy
use, strains of staphylococci resistant to vanco-
mycin have emerged. This is an example of what
can be termed ‘Levy’s Law of Antibiotics’. Use of
antibacterial drugs leads, perhaps inevitably, to
bacterial resistance, which increases the need for
new antibiotics, which would then select for new
resistance phenotypes [17]. The awareness of the
relationship between use and emerging resistance
has led to efforts to decrease, even restrict,
antibiotic use, and therefore decrease the positive
inﬂuence of resistance on the market and decrease
market potential.
At $26 bn, the antibacterial marketplace is
large, but has been growing at an increasingly
modest rate over the past four years. What is clear
is that the market for parenteral (injectable)
antibiotics (most often used for serious, hospital
infections) is growing faster than for oral
antibiotics most commonly used for commu-
nity-acquired infections although the parenteral
market is only about 30% of total sales. More than
80% of the total antibacterial sales represent
branded products as opposed to generics, dem-
onstrating a surprising resistance to generic com-
petition in this area. Several major ($500 m to
almost $2 bn annual sales) products, however, are
about to lose exclusivity in the major markets over
the next 5–10 years, if not sooner, due to chal-
lenges of patent validity. This increased amount
of generic competition may well lead to a signi-
ﬁcant market contraction; but perhaps it is more
the fear of market contraction; rather than the
commercial reality of an expanding market, that
has further discouraged some companies.
SOLVING THE PROBLEM
There is much that can be done to re-engage
industry in antibacterial research. Such solutions
have been proposed in recent discussions among
PhRMA, the FDA and the IDSA [11,18]. Included
among these are providing clearer guidelines
for the development of novel antibacterials as
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discussed above and taking a more imaginative
approach to clinical trials design which would
allow for smaller trials. Other potential solutions,
including extension of product exclusivity, will
require legislative initiatives. It is also incumbent
upon the pharmaceutical industry to become
more efﬁcient in its drug discovery and develop-
ment processes. Many have already quietly but
radically changed their business models to
address this. But, perhaps most critical of all, it
is necessary for the academic community to
improve the study of bacterial physiology and
resistance because, to put it simply, you cannot
build a good house on a rotten foundation.
CONCLUSIONS
Coincident with the increase in the number of
multidrug resistant bacterial infections has been a
diminution in the quantity and quality of indus-
trial antibacterial research, resulting in a very dry
pipeline of new antibacterial drugs. The reasons
for this decline are many, including industry
consolidation combined with decreased produc-
tivity of research and development efforts,
increased regulatory requirements, decreased
respect for intellectual property, and the per-
ceived potential for contraction in what already is
the most crowded and confused pharmaceutical
market. The resulting perfect storm is already
having dire consequences for patients who have
untreatable infections while public, private and
political concerns have shown little inclination to
act. Drugs discovered today will take longer than
a decade to reach clinical practice under today’s
regulatory regime. Therefore, as the situation
becomes more dire, the prediction here is that
draconian and expensive infectious disease con-
trol measures will become de rigueur in many
hospitals, and agents with compromised utility
and safety will be employed in our desperation to
deal with this underappreciated crisis.
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